HighTower Advisors
INMB icon

HighTower Advisors’s INmune Bio INMB Stock Holding History

HighTower Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6K Buy
+12,664
New +$17.5K ﹤0.01% 3767

Other funds holding INMB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $11.8B AUM 25.68% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
AHL
Abel Hall LLC Baton Rouge, Louisiana $579M AUM 54.21% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HighTower Advisors's INMB Position: Q2 2026 in Review

HighTower Advisors opened a new position in INmune Bio (INMB) in Q2 2026: 12,664 shares worth $20.6K. The stake represents ﹤0.01% of the portfolio and ranks #3767 among its holdings.

30 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • HighTower Advisors held 12,664 shares of INmune Bio worth $20.6K as of Q2 2026.
  • INmune Bio was a new HighTower Advisors position in Q2 2026.
  • INmune Bio made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #3767 holding.
  • 30 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.